Tumor Progression in the LPB-Tag Transgenic Model of Prostate Cancer is Altered by Vitamin D Receptor and Serum Testosterone Status

Overview

Journal J Steroid Biochem Mol Biol

Specialties Biochemistry
Molecular Biology

Date 2010 Mar 30

PMID 20347977

Citations 18

Authors

Sarah Mordan-McCombs

Theodore Brown

Wei-Lin Winnie Wang

Ann-Christin Gaupel

JoEllen Welsh

Martin Tenniswood

Affiliations

Soon will be listed here.

Abstract

Previous studies have suggested that 1,25 dihydroxyvitamin D(3) (1,25(OH)2D3) induces cell cycle arrest and/or apoptosis in prostate cancer cells in vitro, suggesting that vitamin D may be a useful adjuvant therapy for prostate cancer and a chemopreventive agent. Most epidemiological data however shows a weak link between serum 25(OH)D3 and risk of prostate cancer. To explore this dichotomy we have compared tumor progression in the LPB-Tag model of prostate in VDR knock out (VDRKO) and wild type (VDRWT) mice. On the C57BL/6 background LPB-Tag tumors progress significantly more rapidly in the VDRKO mice. VDRKO tumors show significantly higher levels of cell proliferation than VDRWT tumors. In mice supplemented with testosterone to restore the serum levels to the normal range, these differences in tumor progression, and proliferation are abrogated, suggesting that there is considerable cross-talk between the androgen receptor (AR) and the vitamin D axis which is reflected in significant changes in steady state mRNA levels of the AR, PCNA, cdk2 survivin and IGFR1 and 2 genes. These alterations may explain the differences between the in vitro data and the epidemiological studies.

Citing Articles

Diverse landscape of genetically engineered mouse models: Genomic and molecular insights into prostate cancer.

Kaushal J, Takkar S, Batra S, Siddiqui J Cancer Lett. 2024; 593:216954.

PMID: 38735382 PMC: 11799897. DOI: 10.1016/j.canlet.2024.216954.

Molecular Basis of Prostate Cancer and Natural Products as Potential Chemotherapeutic and Chemopreventive Agents.

Bai B, Chen Q, Jing R, He X, Wang H, Ban Y Front Pharmacol. 2021; 12:738235.

PMID: 34630112 PMC: 8495205. DOI: 10.3389/fphar.2021.738235.

Non-Musculoskeletal Benefits of Vitamin D beyond the Musculoskeletal System.

Zhang S, Miller D, Li W Int J Mol Sci. 2021; 22(4).

PMID: 33669918 PMC: 7924658. DOI: 10.3390/ijms22042128.

Controversies in Vitamin D: A Statement From the Third International Conference.

Giustina A, Bouillon R, Binkley N, Sempos C, Adler R, Bollerslev J JBMR Plus. 2020; 4(12):e10417.

PMID: 33354643 PMC: 7745884. DOI: 10.1002/jbm4.10417.

The Role of Nuclear Receptors in Prostate Cancer.

Shiota M, Fujimoto N, Kashiwagi E, Eto M Cells. 2019; 8(6).

PMID: 31212954 PMC: 6627805. DOI: 10.3390/cells8060602.

References

Zhuang S, Burnstein K . Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology. 1998; 139(3):1197-207. DOI: 10.1210/endo.139.3.5770. View

Yang E, Burnstein K . Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. J Biol Chem. 2003; 278(47):46862-8. DOI: 10.1074/jbc.M306340200. View

Cano P, Godoy A, Escamilla R, Dhir R, Onate S . Stromal-epithelial cell interactions and androgen receptor-coregulator recruitment is altered in the tissue microenvironment of prostate cancer. Cancer Res. 2007; 67(2):511-9. DOI: 10.1158/0008-5472.CAN-06-1478. View

Damber J, Aus G . Prostate cancer. Lancet. 2008; 371(9625):1710-21. DOI: 10.1016/S0140-6736(08)60729-1. View

Lou Y, Laaksi I, Syvala H, Blauer M, Tammela T, Ylikomi T . 25-hydroxyvitamin D3 is an active hormone in human primary prostatic stromal cells. FASEB J. 2003; 18(2):332-4. DOI: 10.1096/fj.03-0140fje. View

Murthy S, Agoulnik I, Weigel N . Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Prostate. 2005; 64(4):362-72. DOI: 10.1002/pros.20251. View

Freedman L . Transcriptional targets of the vitamin D3 receptor-mediating cell cycle arrest and differentiation. J Nutr. 1999; 129(2S Suppl):581S-586S. DOI: 10.1093/jn/129.2.581S. View

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Peehl D, Skowronski R, Leung G, Wong S, Stamey T, Feldman D . Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res. 1994; 54(3):805-10. View

10.

Kasper S, Sheppard P, Yan Y, Pettigrew N, Borowsky A, Prins G . Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. Lab Invest. 1998; 78(3):319-33. View

11.

Platz E, Leitzmann M, Hollis B, Willett W, Giovannucci E . Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control. 2004; 15(3):255-65. DOI: 10.1023/B:CACO.0000024245.24880.8a. View

12.

Leman E, Arlotti J, Dhir R, Getzenberg R . Vitamin D and androgen regulation of prostatic growth. J Cell Biochem. 2003; 90(1):138-47. DOI: 10.1002/jcb.10605. View

13.

Hidalgo A, Paredes R, Garcia V, Flynn G, Johnson C, Trump D . Altered VDR-mediated transcriptional activity in prostate cancer stroma. J Steroid Biochem Mol Biol. 2007; 103(3-5):731-6. DOI: 10.1016/j.jsbmb.2006.12.072. View

14.

Bao B, Hu Y, Ting H, Lee Y . Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells. Oncogene. 2004; 23(19):3350-60. DOI: 10.1038/sj.onc.1207461. View

15.

Kivineva M, Blauer M, Syvala H, Tammela T, Tuohimaa P . Localization of 1,25-dihydroxyvitamin D3 receptor (VDR) expression in human prostate. J Steroid Biochem Mol Biol. 1998; 66(3):121-7. DOI: 10.1016/s0960-0760(98)00054-5. View

16.

Blutt S, Polek T, Stewart L, Kattan M, Weigel N . A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice. Cancer Res. 2000; 60(4):779-82. View

17.

Mordan-McCombs S, Brown T, Zinser G, Welsh J, Tenniswood M . Dietary calcium does not affect prostate tumor progression in LPB-Tag transgenic mice. J Steroid Biochem Mol Biol. 2007; 103(3-5):747-51. PMC: 1950667. DOI: 10.1016/j.jsbmb.2006.12.073. View

18.

Li Y, Pirro A, Amling M, Delling G, Baron R, Bronson R . Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. Proc Natl Acad Sci U S A. 1997; 94(18):9831-5. PMC: 23277. DOI: 10.1073/pnas.94.18.9831. View